How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million not $300 million? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. With the ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Reopening conflict between UC and Broad Institute, patent office takes new look at CRISPR history UC Berkeley’s Jennifer Doudna is generally credited as a leader of the team that invented a key CRISPR ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about the much-awaited CRISPR-based drug Casgevy, discuss the ...

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...

Gene editing holds the promise to revolutionize healthcare. But there are only a handful of stocks available for investing in the technology. One of the leaders is Intellia Therapeutics, Inc. (NASDAQ: ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

A History of the Human Brain: From the Sea Sponge to CRISPR, How Our Brain Evolved, by Bret Stetka; Timber Press, 2021 Treat yourself to reading this book. On the subjects that draw your interest, and ...

Using CRISPR, researchers have crafted a technique to study mammalian development in exceptional detail, according to a report published in Science yesterday (August 9). “This method allows us to take ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

How did Intellia Therapeutics rise to become one of the most successful gene-editing pioneers? Here's the story behind the biotech and its stock. Intellia Therapeutics is a biotech that focuses on ...